Investigational drug · Phase 2
AZD4205
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-small Cell Lung Cancer, Peripheral T-cell Lymphoma, Peripheral T Cell Lymphoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
0 still active
All registered trials
10
Any phase or sponsor naming "AZD4205"
First trial start
2022
Mar 17, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AZD4205", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-small Cell Lung Cancer
- Peripheral T-cell Lymphoma
- Peripheral T Cell Lymphoma
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "AZD4205" as an intervention, largest first.
Dizal PharmaceuticalsIndustry
NCT04105010 · 171 participants · Start Sep 10, 2019 · Primary completion Oct 12, 2023
Drug: golidocitinib · For: Relapsed or Refractory Peripheral T Cell Lymphoma
Sites: New Haven, Connecticut; Atlanta, Georgia; St Louis, Missouri · 50 sites in all
Dizal PharmaceuticalsIndustry
NCT03728023 · 66 participants · Start Nov 12, 2018 · Primary completion Aug 20, 2019
Drug: AZD4205; Placebo · For: Healthy Volunteers
Sites: Secaucus, New Jersey
Dizal PharmaceuticalsIndustry
NCT06511895 · 57 participants · Start May 31, 2022 · Primary completion Oct 17, 2025
Drug: AZD4205 · For: Peripheral T Cell Lymphoma
Sites: Hefei, China; Beijing, China; Chongqing, China · 19 sites in all
Dizal PharmaceuticalsIndustry
NCT06511869 · 48 participants · Start Mar 17, 2022 · Primary completion Mar 31, 2025
Drug: AZD4205 · For: Peripheral T-cell Lymphoma
Sites: Hefei, China; Beijing, China; Chongqing, China · 23 sites in all
- Go-CHOP as the Frontline Therapy for PTCLStatus unknown
Henan Cancer HospitalGovernment (non-federal)
NCT05963347 · 45 participants (planned) · Start Aug 3, 2023 · Primary completion Jul 30, 2025
Drug: Golidocitinib; CHOP Regimen · For: Peripheral T Cell Lymphoma
Sites: Zhengzhou, China
Dizal PharmaceuticalsIndustry
NCT05486949 · 32 participants · Start Jul 27, 2022 · Primary completion Oct 8, 2022
Drug: AZD4205 and carbamazepine; AZD4205 and itraconazole · For: Healthy Subjects
Sites: Lenexa, Kansas
Dizal PharmaceuticalsIndustry
NCT06295432 · 30 participants · Start Jun 1, 2023 · Primary completion Jun 8, 2026
Drug: DZD9008+AZD4205 · For: Non-small Cell Lung Cancer
Sites: Guangzhou, China; Wuhan, China; Xi'an, China · 4 sites in all
- Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLCRecruiting
Cancer Institute and Hospital, Chinese Academy of Medical SciencesAcademic, hospital or other
NCT07110103 · 20 participants (planned) · Start Oct 31, 2025 · Primary completion Mar 31, 2027
Drug: golidocitinib with PD-1 inhibitors · For: SCLC; SCLC, Extensive Stage
Sites: Beijing, China; Chongqing, China
Dizal PharmaceuticalsIndustry
NCT03450330 · 10 participants · Start Apr 16, 2018 · Primary completion Sep 3, 2019
Drug: AZD4205 · For: Nonsmall Cell Lung Cancer
Sites: Sydney, Australia; Heidelberg, Australia; Melbourne, Australia · 4 sites in all
Dizal PharmaceuticalsIndustry
NCT04225208 · 8 participants · Start Jan 6, 2020 · Primary completion Mar 2, 2020
Drug: [14C]-AZD4205, single 50 mg oral dose administrated on day 1 · For: Healthy Volunteers
Sites: Baltimore, Maryland
Newest research
PubMed records naming it or its code names, newest first.
- Efficient chemical reprogramming of human T cells into functional megakaryocytes and platelets.
Qin J, Hua Z, Zhao X, et al. · Sci Adv 2026
- The role of the tumour microenvironment in lung cancer and its therapeutic implications.
Edirisinghe DT, Kaur J, Lee YQ, et al. · Med Oncol 2025
- Identification of Thieno[3,2-d]pyrimidine derivatives as potent and selective Janus Kinase 1 inhibitors.
Kim Y, Jeon E, Ahn H, et al. · Eur J Med Chem 2025
- Discovery of (2R)-N-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor.
Su Q, Banks E, Bebernitz G, et al. · J Med Chem 2020
Also in development for Non-small Cell Lung Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.